Dmitri Simberg
Overview
Explore the profile of Dmitri Simberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
1790
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Moein Moghimi S, McCullough R, Simberg D
Mol Ther
. 2023 Feb;
31(3):605-606.
PMID: 36754053
No abstract available.
12.
Gaikwad H, Wang G, Li Y, Bourne D, Simberg D
Adv Nanobiomed Res
. 2023 Jan;
2(8).
PMID: 36591390
Red blood cells (RBCs) are natural carriers for sustained drug delivery, imaging, and in vivo sensing. One of the popular approaches to functionalize RBCs is through lipophilic anchors, but the...
13.
Moghimi S, Haroon H, Yaghmur A, Simberg D, Trohopoulos P
J Control Release
. 2022 Sep;
351:432-443.
PMID: 36152807
The contribution of the complement system to non-specific host defence and maintenance of homeostasis is well appreciated. Many particulate systems trigger complement activation but the underlying mechanisms are still poorly...
14.
Balyasnikova I, Zannikou M, Wang G, Li Y, Duffy J, Levine R, et al.
J Control Release
. 2022 Jul;
349:413-424.
PMID: 35817279
Glioblastoma (GBM) is the most devastating and aggressive brain tumor in adults. Hidden behind the blood-brain and blood-tumor barriers (BBTB), this invasive type of brain tumor is not readily accessible...
15.
Gaikwad H, Li Y, Wang G, Li R, Dai S, Rester C, et al.
ACS Nano
. 2022 May;
PMID: 35507641
Many aspects of innate immune responses to SARS viruses remain unclear. Of particular interest is the role of emerging neutralizing antibodies against the receptor-binding domain (RBD) of SARS-CoV-2 in complement...
16.
Moein Moghimi S, Simberg D
Mol Ther
. 2022 Apr;
30(6):2109-2110.
PMID: 35487214
No abstract available.
17.
Li Y, Lofchy L, Wang G, Gaikwad H, Fujita M, Simberg D
ACS Nano
. 2022 Mar;
16(4):6349-6358.
PMID: 35343675
PEGylated liposome is the cornerstone platform for modern drug delivery. Unfortunately, as exemplified by PEGylated liposomal doxorubicin (aka Doxil), altered doxorubicin pharmacokinetics causes off-target accumulation in the skin, including the...
18.
Zhang W, Gaikwad H, Groman E, Purev E, Simberg D, Wang G
J Magn Magn Mater
. 2021 Nov;
541.
PMID: 34720339
Cell based therapies including chimeric antigen receptor (CAR) T cells are promising for treating leukemias and solid cancers. At the same time, there is interest in enhancing the functionality of...
19.
Lipid nanoparticle formulation of niclosamide (nano NCM) effectively inhibits SARS-CoV-2 replication
Wang G, Gaikwad H, McCarthy M, Gonzalez-Juarrero M, Li Y, Armstrong M, et al.
Precis Nanomed
. 2021 Oct;
4(1):724-737.
PMID: 34676370
As exemplified by the COVID-19 pandemic, highly infective respiratory viruses can spread rapidly in the population because of lack of effective approaches to control viral replication and spread. Niclosamide (NCM)...
20.
Li Y, Wang G, Griffin L, Banda N, Saba L, Groman E, et al.
J Control Release
. 2021 Sep;
338:548-556.
PMID: 34481928
The complement system plays a key role in opsonization and immune clearance of engineered nanoparticles. Understanding the efficiency, inter-subject, and inter-strain differences of complement opsonization in preclinical species can help...